Cell therapy in bone healing disorders

Main Article Content

Marcus Jäger *
Philippe Hernigou
Christoph Zilkens
Monika Herten
Xinning Li
Johannes Fischer
Rüdiger Krauspe
(*) Corresponding Author:
Marcus Jäger | Jaeger@med.uni-duesseldorf.de


In addition to osteosynthetic stabilizing techniques and autologous bone transplantations, so-called orthobiologics play an increasing role in the treatment of bone healing disorders. Besides the use of various growth factors, more and more new data suggest that cell-based therapies promote local bone regeneration. For ethical and biological reasons, clinical application of progenitor cells on the musculoskeletal system is limited to autologous, postpartum stem cells. Intraoperative one-step treatment with autologous progenitor cells, in particular, delivered promising results in preliminary clinical studies. This article provides an overview of the rationale for, and characteristics of the clinical application of cell-based therapy to treat osseous defects based on a review of existing literature and our own experience with more than 100 patients. Most clinical trials report successful bone regeneration after the application of mixed cell populations from bone marrow. The autologous application of human bone marrow cells which are not expanded ex vivo has medico-legal advantages. However, there is a lack of prospective randomized studies including controls for cell therapy for bone defects. Autologous bone marrow cell therapy seems to be a promising treatment option which may reduce the amount of bone grafting in future.

Downloads month by month


Download data is not yet available.

Article Details

Author Biography

Marcus Jäger, Heinrich-Heine-University Medical School, Dusseldorf,

Deputy-Orthopaedist-In-Chief, Head Orthopaedic Research Lab

Most read articles by the same author(s)